Cargando…

FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures

FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Kah Keng, Gascoyne, Duncan M., Soilleux, Elizabeth J., Lyne, Linden, Spearman, Hayley, Roncador, Giovanna, Pedersen, Lars M., Møller, Michael B., Green, Tina M., Banham, Alison H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288160/
https://www.ncbi.nlm.nih.gov/pubmed/27224915
http://dx.doi.org/10.18632/oncotarget.9507
_version_ 1782504277711781888
author Wong, Kah Keng
Gascoyne, Duncan M.
Soilleux, Elizabeth J.
Lyne, Linden
Spearman, Hayley
Roncador, Giovanna
Pedersen, Lars M.
Møller, Michael B.
Green, Tina M.
Banham, Alison H.
author_facet Wong, Kah Keng
Gascoyne, Duncan M.
Soilleux, Elizabeth J.
Lyne, Linden
Spearman, Hayley
Roncador, Giovanna
Pedersen, Lars M.
Møller, Michael B.
Green, Tina M.
Banham, Alison H.
author_sort Wong, Kah Keng
collection PubMed
description FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prognosis activated B-cell (ABC)-like subtype display partially blocked plasma cell differentiation. FOXP2 protein expression was detected in ABC-DLBCL cell lines, and in primary DLBCL samples tumoral FOXP2 protein expression was detected in both germinal center B-cell-like (GCB) and non-GCB DLBCL. In biopsies from DLBCL patients treated with immunochemotherapy (R-CHOP), ≥ 20% nuclear tumoral FOXP2-positivity (n = 24/158) correlated with significantly inferior overall survival (OS: P = 0.0017) and progression-free survival (PFS: P = 0.0096). This remained significant in multivariate analysis against either the international prognostic index score or the non-GCB DLBCL phenotype (P < 0.05 for both OS and PFS). Expression of BLIMP1, a marker of plasmacytic differentiation that is commonly inactivated in ABC-DLBCL, did not correlate with patient outcome or FOXP2 expression in this series. Increased frequency of FOXP2 expression significantly correlated with FOXP1-positivity (P = 0.0187), and FOXP1 co-immunoprecipitated FOXP2 from ABC-DLBCL cells indicating that these proteins can co-localize in a multi-protein complex. FOXP2-positive DLBCL had reduced expression of HIP1R (P = 0.0348), which is directly repressed by FOXP1, and exhibited distinct patterns of gene expression. Specifically in ABC-DLBCL these were associated with lower expression of immune response and T-cell receptor signaling pathways. Further studies are warranted to investigate the potential functional cooperativity between FOXP1 and FOXP2 in repressing immune responses during the pathogenesis of high-risk DLBCL.
format Online
Article
Text
id pubmed-5288160
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-52881602017-02-07 FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures Wong, Kah Keng Gascoyne, Duncan M. Soilleux, Elizabeth J. Lyne, Linden Spearman, Hayley Roncador, Giovanna Pedersen, Lars M. Møller, Michael B. Green, Tina M. Banham, Alison H. Oncotarget Research Paper FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prognosis activated B-cell (ABC)-like subtype display partially blocked plasma cell differentiation. FOXP2 protein expression was detected in ABC-DLBCL cell lines, and in primary DLBCL samples tumoral FOXP2 protein expression was detected in both germinal center B-cell-like (GCB) and non-GCB DLBCL. In biopsies from DLBCL patients treated with immunochemotherapy (R-CHOP), ≥ 20% nuclear tumoral FOXP2-positivity (n = 24/158) correlated with significantly inferior overall survival (OS: P = 0.0017) and progression-free survival (PFS: P = 0.0096). This remained significant in multivariate analysis against either the international prognostic index score or the non-GCB DLBCL phenotype (P < 0.05 for both OS and PFS). Expression of BLIMP1, a marker of plasmacytic differentiation that is commonly inactivated in ABC-DLBCL, did not correlate with patient outcome or FOXP2 expression in this series. Increased frequency of FOXP2 expression significantly correlated with FOXP1-positivity (P = 0.0187), and FOXP1 co-immunoprecipitated FOXP2 from ABC-DLBCL cells indicating that these proteins can co-localize in a multi-protein complex. FOXP2-positive DLBCL had reduced expression of HIP1R (P = 0.0348), which is directly repressed by FOXP1, and exhibited distinct patterns of gene expression. Specifically in ABC-DLBCL these were associated with lower expression of immune response and T-cell receptor signaling pathways. Further studies are warranted to investigate the potential functional cooperativity between FOXP1 and FOXP2 in repressing immune responses during the pathogenesis of high-risk DLBCL. Impact Journals LLC 2016-05-20 /pmc/articles/PMC5288160/ /pubmed/27224915 http://dx.doi.org/10.18632/oncotarget.9507 Text en Copyright: © 2016 Wong et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Wong, Kah Keng
Gascoyne, Duncan M.
Soilleux, Elizabeth J.
Lyne, Linden
Spearman, Hayley
Roncador, Giovanna
Pedersen, Lars M.
Møller, Michael B.
Green, Tina M.
Banham, Alison H.
FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
title FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
title_full FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
title_fullStr FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
title_full_unstemmed FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
title_short FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
title_sort foxp2-positive diffuse large b-cell lymphomas exhibit a poor response to r-chop therapy and distinct biological signatures
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288160/
https://www.ncbi.nlm.nih.gov/pubmed/27224915
http://dx.doi.org/10.18632/oncotarget.9507
work_keys_str_mv AT wongkahkeng foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures
AT gascoyneduncanm foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures
AT soilleuxelizabethj foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures
AT lynelinden foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures
AT spearmanhayley foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures
AT roncadorgiovanna foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures
AT pedersenlarsm foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures
AT møllermichaelb foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures
AT greentinam foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures
AT banhamalisonh foxp2positivediffuselargebcelllymphomasexhibitapoorresponsetorchoptherapyanddistinctbiologicalsignatures